Stanislav Vartanov, MS’ Post

Adjuvanted vs. Non-Adjuvanted Vaccines: What’s the Difference? 💉🧬 When we talk about flu and COVID-19 vaccines, one scientific detail that often gets overlooked is whether the vaccine contains an adjuvant. 🔹 What is an adjuvant? An adjuvant is a substance added to a vaccine to enhance the immune response. It helps the body “see” the vaccine antigen more clearly, making the response stronger and often longer-lasting. 🔹 Flu Vaccines Adjuvanted flu vaccines (like Fluad) are especially designed for older adults, whose immune systems may not respond as strongly. These vaccines trigger a more robust antibody response. Non-adjuvanted flu vaccines are effective as well but may not provide the same level of immune stimulation in high-risk populations. 🔹 COVID-19 Vaccines Most mRNA vaccines (Pfizer, Moderna) don’t contain traditional adjuvants — the lipid nanoparticles themselves help stimulate immunity. Protein-based vaccines (like Novavax) often use adjuvants (e.g., Matrix-M) to boost immune response. 💡 Why it matters: Adjuvants can improve protection in populations with weaker immune systems (older adults, immunocompromised). They may also reduce the amount of antigen needed per dose, helping scale global vaccine supply. As vaccine science continues to evolve, understanding these differences helps us see why certain vaccines are recommended for specific groups — and why innovation in adjuvants is just as important as innovation in vaccine platforms. https://lnkd.in/g2SYVB4r

🌟 Advancements in Pertussis Vaccination: Optimizing Cationic Lipid-Based Adjuvants 🌟 I’m thrilled to share highlights from a recent study by Tavonga T. Mandava and colleagues that focuses on the design and evaluation of a novel cationic lipid nanoparticle-based pertussis vaccine. This research is pivotal in addressing the resurgence of pertussis cases globally, especially among vulnerable populations. 🔬 Key Insights: Innovative Approach: The study employed a Design-of-Experiments (DoE) methodology to optimize the lipid composition of a triple adjuvanted vaccine (L-TriAdj), enhancing its physicochemical properties and immunogenicity. Enhanced Immune Response: Results indicated that increasing the alkyl chain length of phosphatidylcholine lipids significantly improved cellular viability, uptake, and the induction of critical cytokines like IL-12 and IFN-γ. Importance of Lipid Composition: The findings underscore that varying the ratio of phosphoethanolamine and phosphatidylcholine lipids influences vaccine performance, with specific formulations leading to robust immune responses. 💡 Conclusion: This research not only provides valuable insights into the formulation of effective pertussis vaccines but also emphasizes the critical role of lipid composition in vaccine efficacy. Moving forward, in vivo studies will be essential to validate the protective capacity of these optimized formulations. Let's continue to innovate and improve our vaccine strategies for better public health outcomes! 💉✨ https://lnkd.in/eX9j-q_N #Vaccines #Immunology #CationicLipids #Pertussis #PublicHealth #Pharmaceuticals #Research

United States Vaccines Market Size, Top 47 Vaccines Brand In-depth Analysis, Insights, and Forecasts to 2033 United States Vaccines Market Size and Trends The United States vaccines market size was valued at USD 29.5 billion in 2024 and is projected to hit around USD 60 billion by 2033, growing at a CAGR of 8.2% during the forecast period 2025 to 2033. United States Vaccine Market Growth Drivers  One of the foremost factors influencing the expansion of the vaccine market in the United States is the rising prevalence of infectious diseases. With the emergence of new pathogens and variants, the demand for effective vaccines has surged. Additionally, advancements in biotechnology and genetic research are leading to the development of more effective and targeted vaccine formulations. Another critical catalyst is the robust investment in vaccine research and development. Government agencies and private organizations alike are funneling funds into vaccine projects, accelerating the pace of innovation. Moreover, regulatory support and streamlined approval processes have encouraged manufacturers to bring new vaccines to market more quickly. More Details @ https://lnkd.in/dTfaMzEP #vaccine #covid #coronavirus #vaccination #health #vaccines #pandemic #corona #trump #pfizer #lockdown #covidvaccine #healthcare #news #freedom #medicine #virus #moderna #science #flu #covidvacccine #india #influenza #memes #vaccineswork #doctor #staysafe #vaccinated #immunization #vaksin

📢 Differences in immunogenicity to the recombinant zoster vaccine in IMID patients undergoing treatment with non-selective or selective JAK inhibitors 💬 In this study, we compared humoral and cellular responses to the recombinant herpes zoster vaccine (Shingrix™) across IMID patients receiving different immunosuppressive therapies. 🔹 JAK inhibitor–treated patients showed significantly reduced seroconversion and impaired CD4⁺ and CD8⁺ T-cell responses compared with those on anti-TNF or methotrexate. 🔹 Non-selective JAK-i (baricitinib, tofacitinib) were associated with the lowest responses, while selective JAK1-i (upadacitinib) performed comparatively better. 🔹 Anti-TNF/MTX patients retained more preserved vaccine-induced immunity. These findings underscore the impact of JAK pathway inhibition on vaccine immunogenicity and the importance of personalized vaccination strategies in immunosuppressed IMID populations. 📄 https://lnkd.in/dExcnuxS #Rheumatology #Vaccines #JAKinhibitors #IMIDs #SSc #SLE #RA #TranslationalImmunology #Shingrix #Autoimmunity

A new industry article examines GeoVax's multi-antigen COVID-19 vaccine approach and its potential as a "game changer" for immunocompromised populations. The article highlights how GEO-CM04S1's dual-targeting of both spike and nucleocapsid proteins generated robust antibody and durable T-cell responses in patients who typically show subpar responses to single-antigen vaccines. Key findings discussed include Phase 2 data where GEO-CM04S1 outperformed an mRNA comparator in CLL patients, leading to the mRNA arm being halted for insufficient immunogenicity. The article also notes the broader industry shift away from single-antigen approaches, with federal health officials citing the need for longer-lasting and broader protection. Read the full article: https://lnkd.in/guZcVAAc #Vaccines #Immunology #Biotech

Cavity Vaccine Update: Inside the Science, Safety Concerns, and Why It’s Still Not Ready for Your Patients Yet https://lnkd.in/gHyK7g3H There’s been a lot of interest in the idea of a cavity vaccine, one that targets the key player in caries, Streptococcus mutans, and two recent reviews give a clear status check. The first, “Dental caries vaccine: are we there yet?” (Patel, 2020) reports that research over the past 40 years has identified major virulence factors of S. mutans (Ag I/II adherence antigen, glucosyltransferases, glucan-binding proteins) that provoke antigen-specific immune responses. Animal studies have shown promising vaccines (e.g., recombinant multigenic DNA or mucosal delivery routes) and adjuvants, but the key takeaway is: despite decades of lab work, no vaccine is yet commercially available for human caries prevention. The author emphasizes the need for multicentre human clinical trials, safety and delivery system issues, and funding momentum. The second, “Developing a Vaccine for Dental Caries / Cavities” (Dental Didactics CE, 2022) complements this by describing the types of vaccine strategies attempted: whole-cell, subunit, synthetic peptides, and both active and passive immunisation. Notably, they highlight a major safety concern: antibodies raised against S. mutans in early trials showed reactivity with human heart and skeletal muscle tissues, a red flag for human application. They note that while animal data are strong, caries is not often considered a life-threatening disease and thus it has not attracted the same public-health funding priority as other vaccines. The science behind a caries vaccine is mature in the pre-clinical stage, we know targets, mechanisms, and delivery routes. But translation to safe, effective human use is not yet achieved. Until a human vaccine clears safety, efficacy and regulatory hurdles, prevention will continue to rely on fluoride, sealants, biofilm control, diet and risk-management. Dental caries vaccine: are we there yet? PubMed https://lnkd.in/gdVG2z4j Developing a Vaccine for Dental Caries / Cavities - Dental Didactics CE https://lnkd.in/gu227ZYi

💡 Don’t miss this comprehensive review by Christian Marx and his co-workers, in collaboration with Thomas Schirrmann, on the crucial role of antibodies in effective pandemic preparedness and response.

This article captures an inflection point in vaccine development, the growing recognition that vulnerable populations need more than what first-generation single-antigen vaccines can provide. GeoVax Labs, Inc.’s GEO-CM04S1 data demonstrates that a multi-antigen MVA approach can generate both robust antibody and durable T-cell responses in immunocompromised patients. The Phase 2 results in CLL patients, where our vaccine succeeded while the mRNA comparator was halted, underscore why broader immune engagement matters for these populations. Worth reading for perspective on the evolving vaccine landscape and the shift toward next-generation platforms. Read the article: https://lnkd.in/esniG85d #Vaccines

Unlocking Spirulina secrets to supercharge vaccines. James Cook University (JCU) researchers have found particles in popular ‘superfood’ Spirulina that could lead to huge advancements in vaccine production and effectiveness. Australia. December 2024 Excerpt: The research paper, led by Dr Farouq Sharifpour, DVM, PhD from JCU’s Australian Institute of Tropical Health & Medicine (AITHM), investigates Spirulina extracellular vesicles (SPEV) and their potential therapeutic benefits. While safely testing on mice, Dr Sharifpour and his team found that SPEV has huge potential as a new class of vaccine adjuvant (substances added to vaccines to make them more effective). Refer to the enclosed announcement to obtain additional information and to access the link to published research in Journal of Extracellular Biology 12 December 2024. https://lnkd.in/eSM9Mauw

GeoVax Labs has presented compelling interim results for its multi-antigen COVID-19 vaccine, GEO-CM04S1, at the World Vaccine Congress Europe 2025, highlighting significant advancements for immunocompromised populations. Researchers demonstrated that the vaccine elicits strong T-cell responses to both Spike and Nucleocapsid antigens, potentially exceeding current mRNA booster performance. The Phase 2 trial focused on patients with hematologic malignancies showed a favorable safety profile with only mild-to-moderate adverse events. Dr. Mark J. Newman, Chief Scientific Officer, emphasized the limitations of existing 'one-size-fits-all' vaccines and presented data suggesting GEO-CM04S1 could provide broader, more durable immunity. The vaccine's unique design aims to address protection gaps for vulnerable patient groups. Interim safety results revealed no serious vaccine-related adverse events, with breakthrough infections remaining mild-to-moderate. These findings underscore the potential of GeoVax's MVA-vectored, multi-antigen approach to enhance COVID-19 vaccine strategies. CEO David Dodd expressed optimism about the vaccine's capacity to protect immunocompromised patients, highlighting the ongoing clinical trials evaluating its effectiveness across different patient populations.